Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update

Core Insights - Connect Biopharma announced positive topline data from its Phase 1 study of IV rademikibart in patients with asthma or COPD, demonstrating rapid improvement in forced expiratory volume in one second (FEV1) [5][2] - The company entered into a securities purchase agreement for $20.2 million equity financing, extending its cash runway into the second half of 2027 [6][2] Development Highlights - Rademikibart's Phase 2 Seabreeze STAT studies for acute asthma and COPD were initiated in 2025, with topline data expected mid-2026 [2][4] - The Phase 3 study results for rademikibart in moderate-to-severe atopic dermatitis (AD) showed rapid and durable efficacy, with ~90% of patients achieving near-maximal responses [4][5] Financial Overview - As of December 31, 2025, the company reported cash, cash equivalents, and short-term investments of $44.3 million, which is expected to fund operations into the second half of 2027 [9][20] - For the three months ended December 31, 2025, the net loss was $15.1 million, or ($0.27) per share, compared to a net loss of $8.9 million, or ($0.16) per share for the same period in 2024 [9][18] Corporate Developments - The company has entered into a private placement agreement to sell 6,130,000 shares at $3.25 per share, with gross proceeds expected to be $20.2 million [6][2] - Connect Biopharma has granted an exclusive license to Simcere Pharmaceutical Co., Ltd. for rademikibart in Greater China, with potential milestone payments up to approximately $110 million [11][9]